855 citations,
June 2009 in “The Journal of Clinical Endocrinology & Metabolism”
The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.
User shared a 4-month progress update on using minoxidil and 1.5 months on finasteride for hair loss. Reactions were mixed, with some expressing disbelief and others feeling inspired to start treatment.
This conversation discussed the potential for a hair loss treatment alternative to minoxidil, with many users debating the economic and health implications of such an option. Some suggested that finasteride could be used as an alternative, while others argued that this would ultimately not benefit pharmaceutical companies due to their reliance on planned obsolescence.
This user discussed using oral minoxidil as a hair loss treatment, and was cautioned against mixing topical minoxidil with water and drinking it due to potential side effects and risks. Other users shared their concerns about the dangers of self-prescribing medications without consulting a doctor.